2021-09-15 Emerging Growth Conference Presentation Rough

New Post Public Reply Private Reply Replies (12) Message Board
z_smith01
2,219
2021-09-15 Emerging Growth Conference Presentation
Rough notes


7years on MONO
No other product has done that





COVID
Person who “really needs to get credit”
Dr. SH
Read papers that SK provided to him

CR single handled started LH trial









SK: re CURE
London pt, Berlin pt
Devoid of CCR5
Working with AMFAR on this project



BTD application was immediately prepared by us
Separating from CRO (AMAREX)
Not getting sequence from CRO
Need to get it from another CRO

SK:
MOA
In order grow beyond 2mm, need it own blood supply







Need 100 to 150 pts to hit p-value of 0.05

SK:
23-69M pts without treatment options
50% of young people with COVID are experiencing LH
Could turn into over 100M people who don’t have treatment options




PH – looking for 3rd PO soon; 2nd PO product has already been used

CD16 – expect 1st pt any day
Will be getting weekly updates on pt enrollment and will update shareholders




SK:
Same stats re NAFLD and NASH








Anthony C.’s leadership, with NP as CEO
Stopped cancer study
Stopped gVHD
Just wanted to focus on COMBO

Hospitals were not paid

Leadership was given back to SK and NP

Don’t think could find any company that has achieved amount raised and dilution in 2020.

SK:
Testimonials

1st
S4 prostate cancer
Miracle cancer drug has arrived
Beyond chemo or radiation
6-1yr to live by 3 different hospitals
Sept 1st, once per week
October, pancreas, liver, lungs
… now end of July (report) one in Feb, on in May
No new growth and no new movement
Study is ending end of month
Live in RTT state
He can inject himself
No side effects
Still on LL today

2nd
S4 Bladder cancer
Not able to take chemo
Used RTT in OH
37 injections
No metastasis
Not live past Dec 2020
Doing well
Works 60+hrs per week
No other treatment other than LL
Will get visual of bladder wall soon
No new metastasis


Q&A:

Q: Academic collaboration?
A: Signed agreement with major academic institution
Waiting for approval for PR
Checkpoint inhibitor

Q: Critical trial in BZ?
A:
ANVISA has given approval based on stability in IV bag
Did study and sent results to ANVISA
Should get cleared asap
Should get 1st pt injected soon

Q: DOJ investigation
A:
RE: DOJ – not supposed to put in filing
It is a fact finding procedure
No new updates

SEC
Have been looking into it for the last year or so
Nothing to report

Q: PH FDA to release data
A:
Can’t disclose confidential details

Q: BLA OCT 15th
A:
Wait, want to talk to FDA
What dates they will submit each package

Q: EUA in BZ impact on FDA
A:
BIOMM pharma
700k vials to BIOMM
If EUA in BZ, then those 700k vials go to BZ and not USA
AE feels very strong on hitting PE at interim analysis

US FDA was excited about our CD12 results

SK: Excited about trials in BZ
Concerned about variants
LL should not be affected by variants; not spike protein dependent

Q: Rev potential in BZ
A: very, very high

Q: Funding until end of year? Burn rate?
A:
Can’t incorporate revenue from BZ into plans b/c don’t have it
Payment is due 90-days after shipment to PH
Hoping shareholders have comfort in how CYDY raised $400M
They are very proud of the fundraising
Now we are in good share
Thinks leadership can raise any amount they want

Q: Preclinical data support use in cirrhosis?
A:
SK – not studied yet
Really rich literature re: cirrhosis

NP –
$420M shareholder money raised
$400M value of inventory today

SK:
In Miami last night meeting with dr. re: rheumatoid arthritis

Q: HIV market size
A:
3 class resistance market is very small
Negotiated with FDA with e.g. Paul Maddon
2 class resistance with limited treatment options
Market is about $1B for COMBO
$6-7B for MONO
Now with right CRO in BZ

And PREP is on top of that

Q: Pt in GvHD? CURE trial?
A:
Leadership change
GvHD was doing wrong population
Corrected it, but now so much more on their plate
Something got approved for GvHD
CRO didn’t have capacity to move as fast as they wanted
So, put on hold

SK:
Originally, myol
Reduced intensity population

COVID pt who had organ transplant was doing poorly before LL then good on LL and then bad after going off LL

Q: LH
A:
Working on PE with FDA and CR
Hoping to get to P2 and adaptive to P3
Working with FDA
If approval comes Q1, 2022, then not enough vials to
Need to pay SAMSUNG now to get product next year
BP puts $350M down payment to Samsung

SK:
LH opens up the adjacent markets

Q: Milestones in the near future?
A:
SK is working with BP
PH
BZ
22 cancer
mTNBC BTD
LH next trial
NASH trial results hopefully in Oct

SK:
Need data to talk to BP
Now have oncology data to show BP
Ultimately CYDY will be a cancer company
Ideally wouldn’t sell the company and would continue building

Q: Share buyback plan
A: No
Working to get drug developed

Q: Plans to partner with BP?
A:
SK – a lot of ways to structure a deal
On multiple fronts now

Q: Will CYDY need partner to fund LH or other trials?
A: Let BP come to CYDY
CYDY does not go to BP

Q: EU or RTT in CA?
A: Pause on EIND and RTT and open clinical trial
Working with agencies on other ways to get the product

Q: Former CRO withholding data?
A: Could be lawsuits
Will defend the shareholders’ value

Q: Contract on desk w/ academic institution?
A: Already signed

Q: Milestone based comp for exec team?
A: Very awkward answer
They now have an independent compensation consultant and compensation committee

Q: Funding trials?
A: Raise funds, pay cash

Q: Capital requirements for 12-24 months?
A: Planning on getting EUA
Will result in $400M in revenue

1B shares to get $200M in funds if have to raise again

Q: Staffing
A: Will bring top leaders in the field
If they do well, then they stay; if not, they will go
Praised Nitya Rae again

Q: Patents on indications presented today
A:
SK – extensive patent portfolio

Q: Price per vial?
A: Don’t disclose

Q: Teaming with CASSAVA for AZ trial?
A:
SK: No, but doing work with INt’l group out of London
Done animal studies for ROT in brain
Very eager to pursue

Q: BTD what issue prevented sending
A:
Own the sequences for each indication, but CRO kept it from them
They will go to court if they have to
Asking FDA to give the sequences from website the FDA has
Takes 3-4 weeks to get from FDA

Q: EAP
A: No longer available
The US and Int’l requests are overwhelming
Couldn’t process all the people asking for the drug

Q: How will fill orders if EUA is given?
A: Have a process

Q: OLE status update?
A: Still have OLE in HIV
But closing it b/c moving away from old CRO
Still haven’t chosen new CRO

Q: Length of time remaining on critical patents?
A: FDA => 12 year exclusivity

Q: Meeting date with PH group?
A:
PH group requested the meeting and it will happen tomorrow night.




CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 47

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 151

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 75

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 68

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Rosenblatt Book Puts Vegas Casino Blind Spots on Display

Updated Category News Views 143

A locked casino floor is supposed to make secrets expensive. That is why the pitch behind ROSENBLATT lands with a little more weight than the usual Vegas chest-thumping: the coming memoir says Darryl Rosenblatt became a million-dollar gambler while using none of his own money, and that casino operators did not grasp the full shape of what had happened for years. Take a...

Continue Reading
NTN Data Breach Raises Hard Questions Beyond Lawsuit

Updated Category News Views 124

Paperwork lifted from a factory network can become a very expensive loose bolt. NTN Bearing Corporation of America, a U.S. maker of bearings and automotive components, has reported a data-security incident that may have exposed sensitive information belonging to current and former employees. A law firm, Edelson Lechtzin LLP, is investigating potential class-action claims....

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading

Top 5 Most Recently Viewed Articles

Allstream Insiders Unveils Industry Talks for Energy Pros

Updated Category News Views 294

Allstream Insiders Launches New Industry Talks Platform HOUSTON -- Allstream Insiders has rolled out an innovative platform called Industry Talks, specifically tailored for professionals within the energy sector. This initiative is designed to offer vital insights and a venue for sharing ideas that resonate in the New Energy markets. Focus on Career Growth and Skills A...

Continue Reading
Exploring Orexo's Pharmaceutical Innovations and IP Strategies

Updated Category News Views 130

Orexo's Insights on Pharmaceutical IP Strategies Orexo, a prominent player in the pharmaceutical industry, is poised to share its extensive knowledge in protecting intellectual property (IP) during an upcoming seminar. This event, organized in collaboration with esteemed law firms Potter Clarkson LLP and Steptoe LLP, aims to equip pharmaceutical companies, biotech firms,...

Continue Reading
Lindblad Expeditions Holdings Plans Tender Offer for Notes

Updated Category News Views 156

Lindblad Expeditions Holdings Begins Tender Offer for Senior Notes Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND) has recently announced the pricing terms of its ongoing tender offer aimed at acquiring any and all of its outstanding 6.750% Senior Secured Notes due 2027. This notable initiative is executed through its wholly-owned subsidiary, Lindblad Expeditions, LLC....

Continue Reading
Key Economic Reports to Influence Markets This Thursday

Updated Category News Views 103

Key Economic Reports to Influence Markets This Thursday As traders gear up for another pivotal day in the financial markets, several key economic reports are expected to be released. These reports could significantly impact market dynamics and sway investor sentiment. This Thursday’s lineup includes essential data on the services sector, jobless claims, and factory...

Continue Reading
Investigation Launch: Zeta Global Holdings Corp Under Scrutiny

Updated Category News Views 160

Zeta Global Holdings Corp (NYSE: ZETA) is stepping into turbulent waters with an intense investigation hovering over its officers and directors regarding possible breaches of fiduciary duty. For shareholders who’ve been riding the wave since at least February 2022, this isn’t just another corporate footnote; it’s a pressing signal that deserves attention. With the...

Continue Reading